Skip to main content
Premium Trial:

Request an Annual Quote

Indivumed, Apceth Partner on Cancer CDx

NEW YORK (GenomeWeb News) – Indivumed and Apceth today announced a partnership to develop technology that can predict patient response to targeted cellular or gene therapies in different cancer types.

The technology, which would allow patients to be stratified based on their response to therapies, would use Indivumed's analytical platform for cancer tissue in order to identify and validate protein biomarkers and targets.

The technology would eventually enable oncologists to identify patients who are best candidates for Apceth's therapeutics, the two companies said.

The project is being funded by the German Federal Ministry of Education and Research as part of the Munich Leading Edge Cluster.

Indivumed is based in Hamburg, Germany and maintains the world's largest tumor database and biobank for the development of new cancer diagnostics, it said. Apceth is headquartered in Much, Germany and develop stem cell and gene therapies.

The Scan

Another Resignation

According to the Wall Street Journal, a third advisory panel member has resigned following the US Food and Drug Administration's approval of an Alzheimer's disease drug.

Novavax Finds Its Vaccine Effective

Reuters reports Novavax's SARS-CoV-2 vaccine is more than 90 percent effective in preventing COVID-19.

Can't Be Used

The US Food and Drug Administration says millions of vaccine doses made at an embattled manufacturing facility cannot be used, the New York Times reports.

PLOS Papers on Frozen Shoulder GWAS, Epstein-Barr Effects on Immune Cell Epigenetics, More

In PLOS this week: genome-wide association study of frozen shoulder, epigenetic patterns of Epstein-Barr-infected B lymphocyte cells, and more.